Regeneron will have a tough job taking on AstraZeneca’s big-selling Ultomiris in the market for paroxysmal nocturnal haemoglobinuria (PNH) therapies – but new biomarker data suggests it could ...

—These quiz questions about paroxysmal nocturnal hemoglobinuria (PNH) are derived from current literature. Are you up to date? At the end of the quiz, compare your score with those of your ...

A police officer killed a man and injured five others at a club restaurant in Gonaïves during a dispute, according to ...

Ilene Weitz, MD, details a few abstracts on paroxysmal nocturnal hemoglobinuria (PNH) treatments that will be presented at ASH 2024, particularly data on danicopan as an add-on to ravulizumab or ...

The mainstay of therapy for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) is Alexion's infusion therapy Soliris, but Novartis' iptacopan could provide an oral option after ...

Please provide your email address to receive an email when new articles are posted on . Ravulizumab led to maintained control of intravascular hemolysis and sustained stable hemoglobin levels ...

In his closing thoughts, Dr De Castro provides a final overview of the ASH conference, highlighting updates in PNH treatment.